RudaCure Inc. signs 联合研究 agreement with 翰林制药 for 干眼症治疗药 (RCI001)
Emerging 生物风投企业 RudaCure Inc. (CEO Yongho Kim) has signed a 联合研发 and investment agreement with 翰林制药 Co., Ltd. (CEO Jaeyoon Kim, Jeongjin Kim), a leading 制药公司 in 眼科 drugs, for the 干眼症治疗药 RCI001.
RCI001, the contracted technology, is a drug that exerts powerful 抗炎和抗氧化效果 through a mechanism that suppresses 炎症激活, thereby alleviating 干眼症. 翰林制药 highly evaluated the commercialization potential of RCI001 based on its faster 泪液分泎, 角膜损伤恢复 capability, and superior 滴眼顺应性 and safety compared to commercially available competing drugs, and decided to pursue joint 研发 and invest in RudaCure.
The total contract value is KRW 15 billion, comprising a fixed licensing fee, separate milestone-based royalties, and investment funds. 翰林制药 will be responsible for process development, GMP production, and supply of RCI001, and will secure domestic sales rights and a certain equity stake in RudaCure. RudaCure will focus on 研发 including 国内外 临床试验, as well as overseas licensing.